Telix Pharmaceuticals analysis: Fair value $17.14 USD vs current $17.50 AUD. High-growth radiopharmaceutical platform with 51.2% revenue growth, therapeutic pipeline worth $2.8bn risk-adjusted value, though execution risks and 8.4x leverage require careful assessment.
View noteHOLD rating with $3.81 fair value vs $4.21 current price. Strong growth prospects offset by integration risks and margin compression pressures.
View noteSouthern Cross Austereo analysis: BUY rating, $3.15 fair value vs $0.84 current price. Digital transformation progressing with LiSTNR profitability achieved.
View noteSuper Retail Group trades at $16.21 vs fair value $13.56, facing digital disruption and margin pressure across four-brand specialty retail portfolio with 55% thesis failure probability.
View noteBUY rating with $1.04 fair value vs $0.54 current price. High-risk transformation story with 562% EBITDA growth but execution challenges.
View noteService Stream trades at $2.07 vs $3.09 fair value (49% upside). EBITDA margins expanding to 6.5%, ROIC 13.2%, net cash $74m.
View noteTrading at $1.48 vs $2.61 fair value (76% upside). Transform-UTM private brand validates strategic transformation. 25% market share, 89 NPS, debt-free balance sheet.
View noteHOLD rating with $8.31 fair value. Exceptional 46.2% EBITDA margins face inevitable compression as 74% ROIC attracts competition. Income-focused opportunity only.
View notePre-revenue gold explorer trading at A$0.047 vs A$0.191 fair value. Dual catalysts: systematic exploration across 1,000km² Eastern Goldfields tenure and US$50m arbitration award. High risk, asymmetric upside.
View noteHOLD rating with $1.78 fair value vs $1.99 current price. Strong 80% annuity model offset by margin compression risks and 53% valuation premium to peers.
View noteSpark New Zealand trading at NZ$2.29 vs fair value NZ$3.07, offering 34% upside through transformation execution and defensive infrastructure advantages in dominant market position.
View noteMedical device manufacturer with 35-40% oral appliance market share. Fair value $0.30 vs current $0.70. EBITDA margins compressing, manufacturing constraints binding.
View note